Characterization and peripheral blood biomarker assessment of anti–Jo‐1 antibody–positive interstitial lung disease
Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, Fertig N, Oddis CV, Kaminski N, Rosas IO, Ascherman DP. Characterization and peripheral blood biomarker assessment of anti–Jo‐1 antibody–positive interstitial lung disease. Arthritis & Rheumatism 2009, 60: 2183-2192. PMID: 19565490, PMCID: PMC2710404, DOI: 10.1002/art.24631.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseMultiplex enzyme-linked immunosorbent assayUsual interstitial pneumoniaC-reactive proteinAntibody-positive individualsEnzyme-linked immunosorbent assayInterstitial pneumoniaSerum levelsLung diseaseLarge cohortBiomarker assessmentIncidence of ILDMyositis-associated interstitial lung diseaseAnti-Jo-1 antibodyPulmonary function test resultsOpen lung biopsyNonspecific interstitial pneumoniaSerum inflammation markersSubset of patientsElevated serum levelsFunction test resultsIdiopathic pulmonary fibrosisDifferent patient subgroupsComputed tomography scanInducible chemokines CXCL9Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer
Rivera MP, Detterbeck FC, Socinski MA, Moore DT, Edelman MJ, Jahan TM, Ansari RH, Luketich JD, Peng G, Monberg M, Obasaju CK, Gralla RJ. Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer. CHEST Journal 2009, 135: 1588-1595. PMID: 19188545, DOI: 10.1378/chest.08-1430.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCisplatinConfidence IntervalsDeoxycytidineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesGemcitabineHumansLung NeoplasmsMaleMaximum Tolerated DoseMiddle AgedNeoadjuvant TherapyNeoplasm StagingPaclitaxelPneumonectomyPreoperative CareProbabilityRespiratory Function TestsRisk AssessmentSurvival AnalysisConceptsNon-small cell lung cancerCell lung cancerSurgical resectionLung cancerPulmonary toxicityResectable early stage non-small cell lung cancerEarly-stage non-small cell lung cancerRandomized phase 2 trialPulmonary function test resultsSecondary end pointsCombination of gemcitabinePhase 2 trialPulmonary function testsGemcitabine-based chemotherapyFunction test resultsTotal lung capacityEligible patientsNonplatinum regimensDyspnea scoreInterstitial pneumonitisPreoperative chemotherapyFunction testsSmoking statusClinical symptomsPreoperative setting
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply